Press releases
These press releases are intended for journalists and analysts/investors.
-
GSK Response to CHOICE Media Release
GSK has previously provided detailed product information and clinical studies to CHOICE and would like to respond to some of the allegation
-
GSK Australia Reports 2013 results to ASIC
GSK Australia reported to the Australian Securities and Investment Commission (ASIC) for 2013, sales of $1,414m
-
Skin Science Facility to Close in Rowville, Victoria
GSK announced today the immediate closure of the Stiefel, skin science facility in Rowville, Victoria
-
2013 Corporate Responsibility Report Published
GSK Australia and New Zealand today published the second annual corporate responsibility report, outlining key achievements in health
-
Positive poppy trial results encourage on-going investigation
Positive results from GSK’s 2013-14 poppy growing trials across Victoria will provide a sound foundation for more targeted trials
-
GSK discloses 2013 payments to Australian healthcare professionals
As part of our ongoing commitment to increase transparency, we are disclosing today, the aggregate amount of fees paid
-
GSK encourages research excellence as award nominations open
GSK has opened nominations for what is regarded as one of the most prestigious research awards available to the Australian science
-
Breo™Ellipta® (fluticasone furoate/vilanterol trifenatate) approved in Australia for Asthma and COPD
GSK Australia and Theravance, Inc. (NASDAQ: THRX) have proudly announced today that the Therapeutic Goods Administration (TGA)
-
GSK innovation starts to relieve the urge to smoke in 50 seconds
GSK Australia launched today a new innovative product Nicabate Oral Strips that starts to* relieve the urge to smoke in just 50 seconds
-
Illuminate your smile with the new Macleans® High Definition™ White range
We all know how important it is to present our best possible self, unleashing the unmistakable feeling of illumination
-
Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer
GlaxoSmithKline plc (LSE:GSK) today announced its decision to stop the MAGRITi trial
-
GSK brings New Zealand to the forefront in new Panadol® brand campaign
A Kiwi father and son will star in a brand new Panadol campaign to be aired on television screens globally
-
GSK Recalls Nicotine Lozenges from Warehouses and Distributors
GSK is in the process of voluntarily recalling from warehouses and distributors a number of batches of nicotine lozenges sold globally
-
New PBS listing for patients with advanced soft tissue sarcoma
Treatment options for advanced Soft Tissue Sarcoma (STS) have been broadened with a new Pharmaceutical Benefits Scheme (PBS)
-
TGA approves GSK’s combination of TAFINLAR®(dabrafenib) and MEKINIST® (trametinib)
GSK Australia announced today that the Therapeutics Goods Administration (TGA) has approved the combination of two oral targeted therapies
-
Supply of Varilrix® and Priorix-Tetra® resumes
GSK recently identified a global manufacturing issue impacting some of our varicella- containing vaccines during routine quality testing
-
Poppy Crop Security Update
GlaxoSmithKline (GSK) is aware that there may be an increased concern in poppy crop security following recent media reports
-
Supply of Varilrix® and Priorix-Tetra®
GSK recently identified a global manufacturing issue relating to some of our varicella-containing vaccines
-
GSK announces changes to its global sales and marketing practices
GSK announced today changes to the way products are marketed and sold to healthcare professionals to further align the company’s activities
-
Poppy Trials Making Positive Progress
Victoria is one step closer to commercial poppy growing, with scientific trials undertaken by GlaxoSmithKline (GSK) Australia
